Proshares Ultra Nasdaq Biotech

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

WHO Procurement Mechanism Selects South African Lab to Produce AIDS Generic Drug

Amgen Advances Obesity Drug MariTide to Phase III Trial

Analysts at Cantor Fitzgerald and Bernstein Give Buy Rating to Gilead Sciences

Gilead Sciences released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.96 B (forecast USD 6.929 B), actual EPS USD 1.61 (forecast USD 1.5805)

Gilead Sciences Raises 2026 Sales Forecast

Gilead Sciences reports Q1 product sales of $6.946 billion

WealthShield Partners LLC builds new position and increases holdings in Gilead Sciences

Amgen Invests in Expanding Its Research Center to Accelerate Drug Development

Vertex Pharmaceuticals Reports Q1 Revenue Below Expectations, EPS Above Expectations

Goldman Sachs Analyst Reiterates Buy Rating on Regeneron Pharmaceuticals

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

MGRX

ARKG

SBIO

LABU

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

Mangoceuticals

VG Health

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Health Care Select Sector SPDR

Danaher Corp. (DHR) shares rose 1.94% to $167.04 on a challenging trading day for the market, outperforming competitors like Thermo Fisher, Abbott, and Medtronic. The stock is still 31.20% below its 52-week high of $242.80. Trading volume reached 5.7 million, surpassing the 50-day average of 4.6 million.

MarketWatch Automated

Danaher

iShares US Medical Devices

SPDR S&P Health Equip

S&P 500

Dow Jones Industrial Average

Thermo Fisher Scentific

Abbott Laboratories

Medtronic

Danaher Corp. Stock Outperforms Competitors On Strong Trading Day

Pfizer Inc. (PFE) shares rose 1.30% to $25.66 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Eli Lilly. Despite the gain, Pfizer remains 10.73% below its 52-week high of $28.75. The trading volume reached 40.9 million, surpassing its 50-day average of 37.8 million.

- Shares of Pfizer Inc. (PFE) increased by 1.30% to $25.66 amid a generally negative trading day for the stock market.  
- The stock remains 10.73% below its 52-week high of $28.75, reached on April 2nd, while competitors like Johnson & Johnson and Eli Lilly saw gains.  
- Trading volume for Pfizer was 40.9 million, surpassing its 50-day average of 37.8 million.

Pfizer

Invesco Nasdaq Biotechnology ETF

Johnson & Johnson

Eli Lilly

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Thermo Fisher Scientific Inc. (TMO) shares rose 1.31% to $447.81 on Tuesday, outperforming a declining market where the S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. This marks the second consecutive day of gains for the stock, which remains 30.46% below its 52-week high of $643.99 reached on January 22nd. Trading volume was 3.4 million, surpassing the 50-day average of 2.2 million.

Factset Research

Thermo Fisher Scientific Inc. Stock Rises Tuesday, Outperforms Market

AMGN

Amgen Inc. (AMGN) shares rose 1.96% to $330.75 on a weak trading day for the market, breaking a three-day losing streak. Despite this gain, the stock remains 15.47% below its 52-week high of $391.29. Competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, with trading volume surpassing its 50-day average.

Amgen

Abbvie

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Regencell Bioscience has announced a registered direct offering of 985,222 ordinary shares priced at $20.30 each, aiming for gross proceeds of approximately $20 million. The offering is led by a $19 million investment from a new institutional investor, with closing expected around May 20, 2026, subject to customary conditions. Univest Securities is the sole placement agent.

PUBT

Regencell Bioscience

Univest Financial

Regencell Bioscience prices 985,222-share registered direct offering at $20.30 each

ABBV

AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended 12.68% below its 52-week high of $244.81. Trading volume reached 7.1 million, surpassing the 50-day average of 6.9 million.

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

ETON

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights to the leishmaniasis drug IMPAVIDO (miltefosine) through a supply and distribution agreement with a Knight Therapeutics affiliate. The rights will take effect on September 26, 2026, contributing to Eton's rare disease portfolio and marking another product launch planned for that year. IMPAVIDO is the only FDA-approved oral treatment for certain forms of leishmaniasis.

Eton Pharmaceuticals

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

OCUL

Ocular Therapeutix reported Q1 2026 results with revenue of $10.79 million and a net loss of $88.61 million, indicating a significant investment burden despite stable revenue. The company's future hinges on the success of its AXPAXLI trials, with a projected revenue of $335.8 million by 2029. Analysts express concerns over rising losses and dependence on AXPAXLI, with fair value estimates ranging from $18.00 to $26.00 per share.

Simplywall

Ocular Therap

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

CMND

Clearmind Medicine Inc. (CMND) has announced a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq's minimum bid price requirement. This will reduce its outstanding shares from 10,190,337 to approximately 1,019,033. The company's authorized share capital remains unchanged. Currently, CMND shares are trading at $0.23, down 38.02%.

nasdaq

Clearmind Medicine

Direxion S&P Biotech Bear 3X

Nasdaq

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

RYTM

Rhythm Pharmaceuticals' CAO Christopher Paul German sold 4,643 shares for $428,131.03 on May 15, 2026, reducing his holdings to zero. The shares were sold at $92.21 each, following option exercises for 4,442 shares at strike prices between $17.97 and $56.69.

Rhythm Pharma

Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03

Proshares Ultra Nasdaq Biotech(BIB.US)